Trustmark National Bank Trust Department lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,920 shares of the medical instruments supplier’s stock after selling 150 shares during the period. Trustmark National Bank Trust Department’s holdings in Becton, Dickinson and were worth $1,636,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Crestwood Advisors Group LLC purchased a new position in shares of Becton, Dickinson and during the first quarter valued at $101,000. North Star Investment Management Corp. increased its position in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares in the last quarter. Parkside Financial Bank & Trust increased its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares in the last quarter. Financial Architects Inc increased its position in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 261 shares in the last quarter. Finally, QCI Asset Management Inc. NY increased its position in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 60 shares in the last quarter. 75.48% of the stock is currently owned by institutional investors and hedge funds.
Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 201.98 on Friday. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $205.94. The company has a 50-day moving average of $197.11 and a 200 day moving average of $185.92. The company has a market cap of $43.08 billion, a PE ratio of 33.55 and a beta of 1.05.
Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.23 by $0.07. The company had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.92 billion. Becton, Dickinson and had a return on equity of 25.37% and a net margin of 10.67%. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.18 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post $9.45 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.45%. Becton, Dickinson and’s payout ratio is currently 48.26%.
COPYRIGHT VIOLATION NOTICE: This piece was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/07/29/trustmark-national-bank-trust-department-has-1-64-million-position-in-becton-dickinson-and-company-bdx.html.
Several equities research analysts have recently issued reports on BDX shares. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research report on Monday, July 17th. Royal Bank Of Canada reiterated a “hold” rating and set a $177.00 price objective on shares of Becton, Dickinson and in a research report on Thursday, April 13th. Evercore ISI upgraded shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $186.00 to $200.00 in a research report on Monday, April 24th. Finally, Cowen and Company reiterated an “outperform” rating and set a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $194.69.
In other Becton, Dickinson and news, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares in the company, valued at approximately $13,171,289.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.40% of the company’s stock.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
